Roche Holding sees China drug sales accounting for half of its total pharmaceutical revenue from the Asia-Pacific region within the next three years due to the country’s higher income levels and healthcare reforms, Bloomberg reported. Luke Miels, Roche’s head of Asia Pacific pharmaceuticals unit said sales in China climbed over 20% last year to US$743 million. Miels said higher incomes and cancer rates have spurred demand for its oncology drugs while China’s US$125 billion healthcare plan will allow more people to access the medical system. "We really see the future in China as being high-quality local generics, and high-tech innovation," he said.
Categories